Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Aoxing Pharma Advances Two Opioid Products in China

publication date: Jul 14, 2015
Aoxing Pharma, a US-headquartered company whose operations are in China, reported positive results from a China registrational trial of buprenorphine/naloxone sublingual tablets as a treatment for opioid dependence. Aoxing has a license to produce narcotic drugs in China, and buprenorphine is an opioid derivative. Last week, Aoxing received marketing approval for its Tilidine Hydrochloride pain medication, a synthetic opioid that is used to treat pain in several countries around the world. More details....

Stock Symbol: (NYSE: AXN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital